Literature DB >> 18259133

Synthesis and structural analysis of polyester prodrugs of norfloxacin.

Marcin Sobczak1, Ewa Witkowska, Ewa Oledzka, Waclaw Kolodziejski.   

Abstract

Two-, three- and four-arm, star-shaped poly(epsilon-caprolactone) and poly(D,L-lactide) homopolymers, and copolymers of epsilon-caprolactone with D,L-lactide were synthesized via ring-opening polymerization of cyclic esters in the presence of glycerol, penthaerythritol and poly(ethylene glycol) as initiators and stannous octoate as a catalyst. Thus obtained oligomers were successfully used in the synthesis of novel macromolecular prodrugs of norfloxacin. The structures of the polymers and prodrugs were elucidated by means of MALDI-TOF MS, NMR and IR studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18259133      PMCID: PMC6245082          DOI: 10.3390/molecules13010096

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


Introduction

Pharmacy is one of the most important areas of application of polymers. They are used as active macromolecular pharmaceutical substances, blood substitutes, auxiliary materials and excipients, in production of macromolecular prodrugs, polymeric drug delivery systems, therapeutic systems, etc. The polymeric prodrugs, drug delivery systems and therapeutic systems exhibit unique pharmacokinetics, body distribution and pharmacological efficacy [1,2,3,4,5,6,7,8,9,10,11,12]. Biodegradable polymers like polylactide (PLA), poly(ε-caprolactone) (PCL) and copolymers of lactides (LA) and ε-caprolactone (CL) are very often used as drug delivery systems. Aliphatic polyesters are usually prepared by ring-opening polymerization (ROP) of the corresponding cyclic monomers, that is D,L-LA, L,L-LA or CL. PLA and PCL can be efficiently obtained by ROP in the presence of ionic initiators as well as coordinative and enzymatic catalysts [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28]. Fluoroquinolones are an important new class of synthetic oral antibacterial agents used against various infections. They work by killing bacteria or preventing their growth. The first discovered and clinically effective quinolone was norfloxacin, that is 1‑ethyl‑6‑fluoro‑1,4‑dihydro‑4‑oxo‑7-(1‑piperazinyl)-3-quinolinecarboxylic acid [29]. Recently, the interaction of norfloxacin with DNA has been considered as useful in the anticancer drug design [30]. Preliminary efforts to prepare nanoparticles of poly(D,L-lactide-co-glycolide) loaded with adsorbed norfloxacin has already been reported [31]. The anticancer selectivity of norfloxacin is supposed to be improved by anchoring the drug using chemical linkage to biodegradable oligomers, which may transport the drug molecules more efficiently and more specifically. We go in the latter scientific direction. In this paper, we describe the synthesis of a series of star-branched polyester prodrugs of norfloxacin. Chemical structures of the synthesized polymers have been confirmed by 1H- and 13C- solution NMR as well as FT-IR spectroscopy. Absolute molecular weights of polymers have been determined using gel permeation chromatography (GPC), end-group analysis and matrix-assisted laser desorption/ionization time‑of‑flight mass spectrometry (MALDI-TOF MS).

Results and Discussion

The homo- and copolymerisation reactions of CL and LA were carried out in the presence of initiators like glycerol (Gl), penthaerythritol (Pet) or poly(ethylene glycol) (PEG), and stannous octoate (SnOct2) as catalyst. Reaction conditions, yields and average molecular weight of obtained polyesters are summarized in Table 1. Under these conditions, cyclic monomers underwent ROP and the low-molecular weight polyesters with chain-end hydroxyl groups were obtained. The synthesized PCL and PLA polymers, and the CL&LA copolymers had two-, three- and four-arm star shapes. A typical reaction scheme is presented in Scheme 1.
Table 1

Homopolymerization and copolymerization of CL and LA in the presence of various initiators and SnOct2.

Monomer(s)/initiator/catalystM/I/CatYield(%)Phys. formMnGPC(Da)PDGPCMnMS(Da)PDMSMnthMnarmcLA
CL/PEG/SnOct2100:2:1≈ 100ss52001.225001.261002600-
CL/Gl/SnOct2150:1.5:1≈ 100ss96001.3--114923200-
CL/Pet/SnOct2200:2:162ss53001.319001.172041300-
LA/PEG/SnOct2100:2:179vl42001.214001.160882100-
LA/Gl/SnOct2150:1.5:165vl84001.3--94522800-
LA/Pet/SnOct2200:2:144vl51001.216001.264721300-
LA&CL/PEG/SnOct250:50:2:192vl39001.2--3277200037
LA&CL/Gl/SnOct275:75:1.5:150vl29001.1--3205100035
LA&CL/Pet/SnOct2100:100:2:145vl31001.2--269080044

Reaction conditions: temp. of 120°C, time – 48h

MnGPC - number-average molecular weight determined by GPC

PDGPC - polydispersity (Mw/Mn) determined by GPC

MnMS - number-average molecular weight determined by MALDI-TOF

PDMS - polydispersity (Mw/Mn) determined by MALDI-TOF

Mnth - theoretical number-average molecular weight of polymer.

For homopolymers: Mnth = [M]/[I] × Mmonomer × yield + Minitiator.

For copolymers: Mnth = [M]/[I] × M comonomer(LA) × yield × cLA + [M]/[I] × M comonomer(CL) × yield × cCL + Minitiator

Mnarm - number-average molecular weight of arm of PCL or PLA, Mnarm = MnGPC/oligomer arm number

cLA – content of the LA units in the copolymer (mol %), calculated from 1H NMR on the basis of the intensity ratio of the main-chain [-C(O)CH(CH3)O-] peak of PLA and the main-chain [-CH2CH2CH2CH2CHOC(O)-] peak of PCL

cCL – content of the CL units in the copolymer (mol %): cCL = 100 – cLA

ss - sticky solid

vl - viscous liquid

Scheme 1

Synthesis scheme for two-, three- and four-arm, star-shaped oligoesters.

Synthesis scheme for two-, three- and four-arm, star-shaped oligoesters. m = 2 (for poly(ethylene glycol)), 3 (for glycerol), 4 (penthaerythritol) Two-, three- and four-arm hydroxyl terminated oligomers were prepared using PEG, Gl and Pet initiators, respectively. The respective reaction yields were in the 79-100, 50-100 and 44-62 % range. Thus, the polymerization yields were dependent on the type of the initiator. PEG was found to be more effective than Gl and Pet. For the CL and LA homopolymers, the number-average molecular weights determined by GPC were in the range 5200-9600 and 4200–8400 Da, respectively, while for the LA&CL copolymer they were in the range 2900–3900 Da. PCL had higher molecular weights than PLA, and the homopolymers had higher molecular weights than the copolymers. In all cases, the polydispersity indexes were within 1.1–1.3 limits. Homopolymerization and copolymerization of CL and LA in the presence of various initiators and SnOct2. Reaction conditions: temp. of 120°C, time – 48h MnGPC - number-average molecular weight determined by GPC PDGPC - polydispersity (Mw/Mn) determined by GPC MnMS - number-average molecular weight determined by MALDI-TOF PDMS - polydispersity (Mw/Mn) determined by MALDI-TOF Mnth - theoretical number-average molecular weight of polymer. For homopolymers: Mnth = [M]/[I] × Mmonomer × yield + Minitiator. For copolymers: Mnth = [M]/[I] × M comonomer(LA) × yield × cLA + [M]/[I] × M comonomer(CL) × yield × cCL + Minitiator Mnarm - number-average molecular weight of arm of PCL or PLA, Mnarm = MnGPC/oligomer arm number cLA – content of the LA units in the copolymer (mol %), calculated from 1H NMR on the basis of the intensity ratio of the main-chain [-C(O)CH(CH3)O-] peak of PLA and the main-chain [-CH2CH2CH2CH2CHOC(O)-] peak of PCL cCL – content of the CL units in the copolymer (mol %): cCL = 100 – cLA ss - sticky solid vl - viscous liquid The chemical structures of the obtained polymers were confirmed by 1H-, 13C-NMR and IR studies (Table 2). A typical 1H-NMR spectrum of the two-armed PCL is shown in Figure 1.
Table 2

1H- and 13C-NMR (CDCl3, δ, ppm) peak assignments and the main IR absorption bands (KBr, cm-1) of the obtained polymers.

PCL-PEG: 1H-NMR: 4.20 (2H, CL-OCH2CH2O-), 4.01 (2H, t, -CH2CH2OC(O)-), 3.70 (2H, t, ‑CH2CH2OH, end group), 3.66 (2H, t, -OCH2CH2O-), 2.24 (2H, t, -CH2CH2COO-), 1.58 (4H, m, ‑CH2CH2COO-), 1.33 (2H, m, ‑CH2CH2CH2CH2CH2-)13C-NMR: 173.1 (-C(O)O-), 70.1 (-OCH2CH2O-), 64.1 (CL-OCH2CH2O-), 63.7 (-CH2CH2OC(O)-), 33.6 (‑CH2CH2COO-), 27.9 (-CH2CH2OC(O)-), 25.1 (-CH2CH2COO-), 24.1 (-CH2CH2CH2CH2CH2-)FTIR: 2943 (υasCH2), 2862 (υsCH2), 1721 (υC=O), 1291 (C-O and C-C) 1240 (υasCOC), 1190 (υOC-O), 1170 (υsCOC), 1157 (C-O and C-C)
PCL-Gl: 1H-NMR: 5.24 (1H, p, =CH-O-), 4.28 (2H, d, -CH2-O-), 4.04 (2H, t, ‑CH2CH2OC(O)-), 3.63 (2H, t, ‑CH2CH2OH, end group), 2.28 (2H, t, -CH2CH2COO-), 1.62 (4H, m, -CH2CH2COO-), 1.35 (2H, m, ‑CH2CH2CH2CH2CH2-)13C-NMR: 173.1 (-C(O)O-), 63.7 (-CH2CH2OC(O)-), 62.1 (-CH2-O-), 33.6 (-CH2CH2COO-), 27.9 (‑CH2CH2OC(O)-), 25.1 (-CH2CH2COO-), 24.1 (-CH2CH2CH2CH2CH2-)FTIR: 2949 (υasCH2), 2865 (υsCH2), 1727 (υC=O), 1293 (C-O and C-C), 1240 (υasCOC), 1190 (υOC-O), 1170 (υsCOC)
PCL- Pet: 1H-NMR: 4.02 (2H, t, -CH2CH2OC(O)-), 3.60 (2H, t, -CH2CH2OH, end group), 2.25 (2H, t, -CH2CH2COO-), 1.59 (4H, m, -CH2CH2COO-), 1.34 (2H, m, -CH2CH2CH2CH2CH2-)13C-NMR: 173.1 (-C(O)O-), 63.7 (-CH2CH2OC(O)-), 63.4 (C-CH2O-), 33.6 (-CH2CH2COO-), 33.3 (C‑CH2O‑), 27.9 (-CH2CH2OC(O)-), 25.1 (-CH2CH2COO-), 24.1 (-CH2CH2CH2CH2CH2-)FTIR: 2948 (υasCH2), 2864 (υsCH2), 1726 (υC=O), 1293 (C-O and C-C), 1238 (υasCOC), 1189 (υOC-O), 1169 (υsCOC)
PLA-PEG: 1H-NMR: 5.17 (1H, q, -CH(CH3)-), 4.36 (1H, q, -CH(CH3)OH, end group), 4.25 (2H, LA-OCH2CH2O-), 3.61 (2H, t, -OCH2CH2O-), 1.58 (3H, d, -CH3)13C-NMR: 169.8 (-C(O)O-), 69.2 (-CH(CH3)-), 16.8 (-CH3).FTIR: 2997 (υasCH3), 2947 (υsCH3), 2882 (υCH), 1760 (υC=O), 1452 (δasCH3), 1348-1388 (δsCH3), 1368‑1360 (δ1CH+δsCH3), 1315-1300 (δ2CH), 1270 (δCH + υCOC), 1215-1185 (υasCOC + rasCH3), 1130 (rasCH3), 1100-1090 (υsCOC), 1045 (υC-CH3), 960-950 (rCH3 + υCC), 875-860 (υC-COO), 760-740 (δC=0), 715-695 (γC=O), 515 (δ1C-CH3 + δCCO), 415 (δCCO), 350 (δ2C-CH3 + δCOC), 300-295 (δCOC + δ2C-CH3), 240 (τCC)
PLA-Gl: 1H-NMR: 5.24(1H, p, =CH-O-), 5.16 (1H, q, -CH(CH3)-), 4.35 (1H, q, ‑CH(CH3)OH, end group), 4.27 (2H, d, -CH2-O-), 1.59 (3H, d, -CH3)13C-NMR: 169.7 (-C(O)O-), 69.1 (-CH(CH3)-), 62.1 (-CH2-O-), 16.7 (-CH3)FTIR: 2997 (υasCH3), 2947 (υsCH3), 2882 (υCH), 1760 (υC=O), 1452 (δasCH3), 1348-1388 (δsCH3), 1368‑1360 (δ1CH+δsCH3), 1315-1300 (δ2CH), 1270 (δCH + υCOC), 1215-1185 (υasCOC + rasCH3), 1130 (rasCH3), 1100-1090 (υsCOC), 1045 (υC-CH3), 960-950 (rCH3 + υCC), 875-860 (υC-COO), 760-740 (δC=0), 715-695 (γC=O), 515 (δ1C-CH3 + δCCO), 415 (δCCO), 350 (δ2C-CH3 + δCOC), 300-295 (δCOC + δ2C-CH3), 240 (τCC)
PLA-Pet: 1H-NMR: 5.17 (1H, q, -CH(CH3)-), 4.36 (1H, q, -CH(CH3)OH, end group), 1.60 (3H, d, -CH3)13C-NMR: 169.6 (-C(O)O-), 69.1 (-CH(CH3)-), 63.5 (C-CH2O-), 33.4 (C‑CH2O‑), 16.7 (-CH3)FTIR: 2998 (υasCH3), 2947 (υsCH3), 2883 (υCH), 1760 (υC=O), 1453 (δasCH3), 1348-1388 (δsCH3), 1368‑1360 (δ1CH+δsCH3), 1315-1300 (δ2CH), 1270 (δCH + υCOC), 1215-1185 (υasCOC + rasCH3), 1132 (rasCH3), 1100-1090 (υsCOC), 1046 (υC-CH3), 960-950 (rCH3 + υCC), 875-860 (υC-COO), 760-740 (δC=0), 715-695 (γC=O), 516 (δ1C-CH3 + δCCO), 415 (δCCO), 351 (δ2C-CH3 + δCOC), 300-295 (δCOC + δ2C-CH3), 242 (τCC)
Copolymers of LA and CL: 1H-NMR: 5.15 (1H, q, -CH(CH3)-), 4.27 (1H, q, -CH(CH3)OH, end group), 4.11 (2H, t, -CH2CH2OC(O)-LA), 4.03 (2H, t, -CH2CH2OC(O)-), 3.67 (2H, t, -CH2CH2OH, end group), 2.37 (2H, t, LA-CH2CH2CH2CH2COO-), 2.29 (2H, t, -CH2CH2COO-), 1.63 (4H, m, ‑CH2CH2COO‑),1.59 (3H, d, -CH3), 1.34 (2H, m, -CH2CH2CH2CH2CH2-), and peaks of Gl, Pet and PEG
Figure 1

1H-NMR spectrum of the two-armed PCL (in CDCl3).

1H- and 13C-NMR (CDCl3, δ, ppm) peak assignments and the main IR absorption bands (KBr, cm-1) of the obtained polymers. 1H-NMR spectrum of the two-armed PCL (in CDCl3). The MALDI-TOF mass spectra of obtained oligomers confirmed that the main product was star-shaped oligoester terminated with hydroxyl group. The mass spectra also revealed a small fraction (presumably below 5 wt %) of cyclic oligolactones. Figure 2 shows typical MALDI-TOF spectra of the polymeric products.
Figure 2

MALDI-TOF spectrum of PLA synthesized in the presence of Pet and SnOct2.

MALDI-TOF spectrum of PLA synthesized in the presence of Pet and SnOct2. The MALDI-TOF spectra of PLA comprise three series of peaks. The main series of prominent peaks (A) corresponds to the PLA molecules terminated with a hydroxyl group (residual mass: 41 Da, Na+ adduct), the second series of smaller peaks (B) also corresponds to the PLA molecules terminated with a hydroxyl group (residual mass: 57 Da, K+ adduct) and the third series of low-intensity peaks (C) corresponds to cyclic molecules (residual mass: 23 Da, Na+ adduct). Populations of PLA chains with both even and odd numbers of LA monomer units (m.u.) can be observed. The presence of the odd number of LA m.u. indicates that under the reaction conditions the polymer chain undergoes inter-molecular transesterification, leading to the exchange of segments. This is a typical phenomenon for the polymerization of lactides [14] In the MALDI-TOF spectra of PCL there are also three series of peaks. The most dominant one is characterized by a mass increment of 114 Da, which is equal to the mass of the repeating PCL unit. This series has been assigned to PCL terminated with a hydroxyl group (residual mass: 41 Da, Na+ adduct) (A). The second series of peaks also corresponds to PCL terminated with a hydroxyl group (residual mass: 57 Da, K+ adduct) (B). In addition, the PCL mass spectrum contains a series of minor peaks corresponding to cyclic molecules (residual mass: 23 Da, Na+ adduct) (C). The average molecular weights determined using MALDI-TOF MS were in the 1900–2500 and 1400–1600 Da ranges for PCL and PLA, respectively. The macromolecular prodrugs were obtained (Scheme 2) from the reactions of the two-, three- and four-arm, star-shaped PCL and PLA homopolymers, and the CL&LA copolymers with norfloxacin (NOR).
Scheme 2

Synthesis of the polyester prodrugs of norfloxacin.

Synthesis of the polyester prodrugs of norfloxacin. The chemical structures of the macromolecular prodrugs were confirmed by 1H- and 13C-NMR, and by IR studies. Typical proton NMR spectra of pure NOR and of the reaction products of the two-armed hydroxyl terminated PCL with NOR are shown in Figure 3 and Figure 4, respectively. All the prodrug spectra have revealed characteristic peaks of norfloxacin, indicating successful preparation of the polymer‑NOR conjugate.
Figure 3

1H-NMR spectrum of NOR (in DMSO).

Figure 4

1H-NMR spectrum of the prodrug PCL(PEG)-NOR (in DMSO).

1H-NMR spectrum of NOR (in DMSO). 1H-NMR spectrum of the prodrug PCL(PEG)-NOR (in DMSO). This work focused at the synthetic aspects of the NOR prodrugs. Kinetics of the NOR release from those polymers is still under study and will be presented in the next paper.

Conclusions

The two-, three- and four-arm, star-shaped poly(ε-caprolactone) and poly(D,L-lactide) homopolymers, and the copolymers of ε-caprolactone with D,L-lactide have been successfully used for the preparation of novel drug delivery systems of norfloxacin. The synthesis of those prodrugs was done in two steps. First, the ring-opening homo- or copolymerization of ε-caprolactone and D,L‑lactide in the presence of initiators (poly(ethylene glycol), pentaerythritol or glycerol) and SnOct2 as a catalyst was carried out. In the second step, the reaction of the polymer or copolymer with norfloxacin was performed. Our method of the synthesis is simple and effective. Thus obtained polyester prodrugs of norfloxacin are good potential candidates to be applied as drug delivery carriers. The latter application requires subsequent careful in vitro and in vivo examinations.

Experimental

General

ε-Caprolactone (CL) (2-Oxepanone, Aldrich 99%) was dried and distilled before use over CaH2 at reduced pressure. 3,6-Dimethyl-1,4-dioxane-2,5-dione (D,L-LA) (rac-lactide, Aldrich 98%) was crystallized from a mixture of dry toluene with hexane and dried under vacuum. Poly(ethylene glycol) (PEG) (Mn = 400, Serva Feinbiochemica), pentaerythritol (Pet) (Aldrich 99%), glycerol (Gl) (Aldrich 99%) and norfloxacin (NOR) (Aldrich 99%) were exhaustively dried under vacuum prior use. Stannous octoate SnOct2 (tin (II) 2-ethylhexanoate, Aldrich 95%), dichloromethane and anhydrous methanol were used as received.

Polymerization procedure

Monomers (CL, LA), initiators (PEG, Pet, Gl) and the SnOct2 catalyst were placed in a 10 mL glass ampule under nitrogen atmosphere. The reaction vessel was then kept standing in a thermostated oil bath at 120 oC over 48 h (Table 1). When the reaction time was completed, the cold reaction product was dissolved in CH2Cl2, precipitated from cold methanol with diluted hydrochloric acid (to wash out the catalyst residue) and dried under vacuum for 72h.

Prodrugs synthesis

The prodrugs were prepared under nitrogen atmosphere at room temperature immediately before use. The polyesters were dissolved in CH2Cl2 (1g/50mL) and this solution was placed in a 150 mL three-necked flask equipped with a stirrer and addtion funnel. A solution of NOR in CH2Cl2 (2g/50mL) was placed in the funnel and added dropwise into the reactor, while the reaction mixture was vigorously stirred. After the addition procedure was completed, the reaction mixture was left stirring for an additional 8 h, then it was washed with dilute hydrochloric acid and water. The washing was continued to fully remove any unreacted drug. The prodrugs isolated from the solution (organic phase) were kept under vacuum at room temperature for no more than one week.

Measurements

The polymerization products were characterized by means of 1H- and 13C-NMR (Varian 300 MHz), and FTIR spectroscopy (Spectrum 1000, Perkin Elmer). The NMR spectra were recorded in CDCl3 or DMSO-d6. The IR spectra were recorded from KBr pellets. Relative molecular mass and molecular mass distributions were determined by MALDI-TOF MS and GCP techniques. The MALDI‑TOF spectra were measured in the linear mode on a Kompact MALDI 4 Kratos analytical spectrometer using a nitrogen gas laser with 2-[(4-hydroxyphenyl)diazenyl] benzoic acid (HABA) as a matrix. GPC measurements were made at 25°C in the tetrahydrofuran solution using Shimadzu C-R4 Chromatopac apparatus. The molecular weights were calibrated with polystyrene standards.

Norfloxacin:

1H-NMR (CDCl3, ppm): 1.61, 3.14, 3.31, 4.33, 6.84, 8.07, 8.69, 8.73; (DMSO, ppm): 1.40, 2.88, 3.21, 4.56, 7.13, 7.87, 8.93, 9.03; 13C-NMR (CDCl3, ppm): 14.7, 46.1, 49.9, 51.3, 103.9, 108.6, 113.2, 137.3, 147.3, 152.1, 155.5, 167.5, 177.3; FTIR (cm-1): 3470 (υOH), 1710 (υCO), 1624 (υC=C i C=N), 1452 (δCH2 i ωCH2),1194 (δCH, γCH i υC-O), 1102 (benzene + pyridine ring breathing), 801 (υC-N i δCH2);
  13 in total

1.  Lipase-catalyzed ring-opening polymerization of lactones to polyesters and its mechanistic aspects.

Authors:  S Namekawa; S Suda; H Uyama; S Kobayashi
Journal:  Int J Biol Macromol       Date:  1999 Jun-Jul       Impact factor: 6.953

2.  Polymeric systems for controlled drug release.

Authors:  K E Uhrich; S M Cannizzaro; R S Langer; K M Shakesheff
Journal:  Chem Rev       Date:  1999-11-10       Impact factor: 60.622

Review 3.  Enzymatic polymerization.

Authors:  S Kobayashi; H Uyama; S Kimura
Journal:  Chem Rev       Date:  2001-12       Impact factor: 60.622

Review 4.  Recent developments in ring opening polymerization of lactones for biomedical applications.

Authors:  Ann-Christine Albertsson; Indra K Varma
Journal:  Biomacromolecules       Date:  2003 Nov-Dec       Impact factor: 6.988

Review 5.  Polymeric prodrugs.

Authors:  K Hoste; K De Winne; E Schacht
Journal:  Int J Pharm       Date:  2004-06-11       Impact factor: 5.875

Review 6.  Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs.

Authors:  Y Takakura; M Hashida
Journal:  Crit Rev Oncol Hematol       Date:  1995-03       Impact factor: 6.312

Review 7.  Polyhydroxyalkanonate derivatives in current clinical applications and trials.

Authors:  Hiroki Ueda; Yasuhiko Tabata
Journal:  Adv Drug Deliv Rev       Date:  2003-04-25       Impact factor: 15.470

8.  Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics.

Authors:  H J Jeon; Y I Jeong; M K Jang; Y H Park; J W Nah
Journal:  Int J Pharm       Date:  2000-10-10       Impact factor: 5.875

Review 9.  Bioconjugation in pharmaceutical chemistry.

Authors:  F M Veronese; M Morpurgo
Journal:  Farmaco       Date:  1999-08-30

10.  Synthesis and properties of star-shaped polylactide attached to poly(amidoamine) dendrimer.

Authors:  Qing Cai; Youliang Zhao; Jianzhong Bei; Fu Xi; Shenguo Wang
Journal:  Biomacromolecules       Date:  2003 May-Jun       Impact factor: 6.988

View more
  7 in total

Review 1.  Antibiotic-containing polymers for localized, sustained drug delivery.

Authors:  Nicholas D Stebbins; Michelle A Ouimet; Kathryn E Uhrich
Journal:  Adv Drug Deliv Rev       Date:  2014-04-18       Impact factor: 15.470

Review 2.  Polyglycerol Hyperbranched Polyesters: Synthesis, Properties and Pharmaceutical and Biomedical Applications.

Authors:  Alexandra Zamboulis; Eirini A Nakiou; Evi Christodoulou; Dimitrios N Bikiaris; Eleana Kontonasaki; Liliana Liverani; Aldo R Boccaccini
Journal:  Int J Mol Sci       Date:  2019-12-09       Impact factor: 5.923

Review 3.  Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules.

Authors:  Joanna Fedorowicz; Jarosław Sączewski
Journal:  Monatsh Chem       Date:  2018-06-07       Impact factor: 1.451

4.  Seeking polymeric prodrugs of norfloxacin. Part 2. Synthesis and structural analysis of polyurethane conjugates.

Authors:  Marcin Sobczak; Katarzyna Nurzyńska; Waclaw Kolodziejski
Journal:  Molecules       Date:  2010-02-05       Impact factor: 4.411

5.  Controlled organocatalyzed d,l-lactide ring-opening polymerizations: synthesis of low molecular weight oligomers.

Authors:  M R Newman; S G Russell; D S W Benoit
Journal:  RSC Adv       Date:  2018-08-14       Impact factor: 4.036

Review 6.  Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Authors:  Ioana-Andreea Lungu; Octavia-Laura Moldovan; Victoria Biriș; Aura Rusu
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

7.  Polymerization of cyclic esters initiated by carnitine and tin (II) octoate.

Authors:  Marcin Sobczak; Waclaw Kolodziejski
Journal:  Molecules       Date:  2009-02-04       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.